中国实用内科杂志2024，Vol.44Issue(7)：567-570,4.DOI:10.19538/j.nk2024070109
阿伐曲泊帕治疗慢性肝病相关性血小板减少症临床疗效分析
Clinical efficacy analysis of Avatrombopag in thrombocytopenia associated with chronic liver disease
摘要
Abstract
Objective To assess the safety and effect of Avatrombopag in real world chronic hepatosis related thrombocytopenia patients.Methods The data of patients with thrombocytopenia related to chronic liver disease who planned to undergo invasive operation and received Avatrombopag treatment in Henan Provincial People's Hospital from March 2021 to October 2023 were collected,and the changes in platelet count,blood transfusion and adverse reactions were recorded and analyzed.Results The overall response rate of Avatrombopag for Chronic hepatosis related thrombocytopenia was 82.0％;The baseline platelet level was(39.45±16.37)× 109/L,The median onset time was 7(5,14)d,The median peak time was 13(6,18)d,The peak platelet count was(123.65±12.22)×109/L,The platelet count increase was(83.79±27.5)× 109/L;9.0％of the patients received platelet transfusion,None of the patients had serious adverse events;The Avatrombopag efficacy was more significant at baseline platelets＜30×109/L(P＜0.05);Platelet count remained above baseline at 28 days of administration(P＜0.0001).Conclusion Avatrombopag can significantly improve the platelet count in Chronic hepatosis related thrombocytopenia patients and reduce the bleeding risk and platelet transfusion rate,without obvious serious adverse effects.关键词
慢性肝病/血小板减少症/阿伐曲泊帕/临床效果/安全性Key words
chronic liver disease/thrombocytopenia/Avatrombopag/clinical effect/safety分类
医药卫生引用本文复制引用
魏迅,秦新萌,马力,康谊..阿伐曲泊帕治疗慢性肝病相关性血小板减少症临床疗效分析[J].中国实用内科杂志,2024,44(7):567-570,4.基金项目
河南省医学科技攻关计划联合共建项目(LHGJ20210034) （LHGJ20210034）
